A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
A molecular assay used in combination with patient-collected samples had similar accuracy to testing with clinician collected samples.
With several SBIR grants from the NIH, the firm is also using its Liquid Scan platform to identify neonatal trophoblast cells in maternal blood samples.
In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
The technology uses a conducting polymer-based electrochemical chip with an array of electrodes and employs an electrical field to release and detect mutations.
The company will use its NeoType Discovery Panel for the trial. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.
The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.
BioReference Lab's GenPath division will notify treating oncologists when a genomic alteration is detected that matches an NCI-MATCH treatment arm.